Cargando…

Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma

• Endometrial mesonephric-like adenocarcinoma (MLA) is a rare and aggressive subtype of epithelial endometrial cancer. • KRAS mutations are characteristic in patients with endometrial MLA. • We report two cases of KRAS-mutated endometrial MLA with excellent and durable responses to lenvatinib and pe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Sherry, Rubinstein, Maria M., Park, Kay J., Konner, Jason A., Makker, Vicky
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Case Reports and Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365456/ https://www.ncbi.nlm.nih.gov/pubmed/34430690 http://dx.doi.org/10.1016/j.gore.2021.100844

Ejemplares similares

Molecular profiling of mesonephric and mesonephric-like carcinomas of cervical, endometrial and ovarian origin
por: Lin, Douglas I., et al.
Publicado: (2020)

The similarities and differences between mesonephric carcinoma and mesonephric-like carcinoma: Two cases
por: Kulkarni, Amita, et al.
Publicado: (2021)

Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series
por: Rose, Peter G., et al.
Publicado: (2023)

Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: A retrospective study of the Memorial Sloan Kettering Cancer Center experience
por: Rubinstein, Maria, et al.
Publicado: (2019)

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
por: Makker, Vicky, et al.
Publicado: (2020)

Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer
por: Mimura, Kaito, et al.
Publicado: (2022)

Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma
por: Hunt, Jonathan T., et al.
Publicado: (2021)

Ipsilateral renal dysgenesis or agenesis with tubulocystic anomalies of the mesonephric duct
por: Joshi, Anagha R., et al.
Publicado: (2023)

Mesonephric-like Differentiation of Endometrial Endometrioid Carcinoma: Clinicopathological and Molecular Characteristics Distinct from Those of Uterine Mesonephric-like Adenocarcinoma
por: Park, Sujin, et al.
Publicado: (2021)

Mesonephric-Like Adenocarcinomas a Rare Tumor: The Importance of Diagnosis
por: Restaino, Stefano, et al.
Publicado: (2022)

Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab
por: Makker, Vicky, et al.
Publicado: (2021)

Mesonephric Adenocarcinoma of the Uterine Cervix Associated with Florid Mesonephric Hyperplasia: A Case Report
por: Abdul-Ghafar, Jamshid, et al.
Publicado: (2013)

Tumor lenvatinib addiction and withdrawal rebound response in patients with advanced endometrial cancer
por: Lam, Clarissa, et al.
Publicado: (2023)

Coexistence of endometrial mesonephric-like adenocarcinoma and endometrioid carcinoma suggests a Müllerian duct lineage: a case report
por: Yano, Mitsutake, et al.
Publicado: (2019)

Mesonephric adenocarcinoma of the cervix: Case report and literature review()
por: Dierickx, A., et al.
Publicado: (2016)

Mesonephric Adenocarcinoma of the Vagina Harboring TP53 Mutation
por: Lee, Hyunjee, et al.
Publicado: (2022)

Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE‐775
por: Yonemori, Kan, et al.
Publicado: (2022)

Serous Carcinoma of the Endometrium with Mesonephric-Like Differentiation Initially Misdiagnosed as Uterine Mesonephric-Like Adenocarcinoma: A Case Report with Emphasis on the Immunostaining and the Identification of Splice Site TP53 Mutation
por: Choi, Sangjoon, et al.
Publicado: (2021)

Primary mesonephric adenocarcinoma of the fallopian tube: A case report
por: Xie, Chuan, et al.
Publicado: (2021)

Mesonephric-like adenocarcinoma of the ovary with co-existent endometriosis: A case report and review of the literature
por: Seay, Kieran, et al.
Publicado: (2020)

Mesonephric-like Adenocarcinoma of the Ovary: Clinicopathological and Molecular Characteristics
por: Koh, Hyun Hee, et al.
Publicado: (2022)

Mesonephric-like Adenocarcinoma of the Uterine Corpus: Comprehensive Immunohistochemical Analyses Using Markers for Mesonephric, Endometrioid and Serous Tumors
por: Kim, Hyunjin, et al.
Publicado: (2021)

Mesonephric Adenocarcinoma of Uterine Cervix: A Case Report and Review of the Literature
por: Nili, Fatemeh, et al.
Publicado: (2021)

A case of pembrolizumab and lenvatinib as an alterntive therapy for leiomyosarcoma
por: Mehta, Naaman, et al.
Publicado: (2023)

Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
por: Taylor, Matthew H., et al.
Publicado: (2020)

Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma
por: Lorusso, Domenica, et al.
Publicado: (2022)

A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update
por: Makker, Vicky, et al.
Publicado: (2023)

Ovarian mesonephric-like adenocarcinoma arising in serous borderline tumor: a case report with complex morphological and molecular analysis
por: Dundr, Pavel, et al.
Publicado: (2020)

Perivascular epithelioid cell tumour and mesonephric adenocarcinoma of the uterine cervix: an unknown co-existence
por: Papoutsis, Dimitrios, et al.
Publicado: (2019)

Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma
por: Lorusso, Domenica, et al.
Publicado: (2023)

Pembrolizumab-induced lichenoid dermatitis treated with dupilumab
por: Park, Jonathan J., et al.
Publicado: (2023)

Mesonephric adenocarcinoma of the vagina: Diagnosis and multimodal treatment of a rare tumor and analysis of worldwide experience
por: Mueller, Iris, et al.
Publicado: (2016)

Endometrioid adenocarcinoma associated with endometrial stromal sarcoma: A rare, often unrecognized collision tumor
por: Kim, Grace, et al.
Publicado: (2015)

Mesonephric-like adenocarcinoma of the ovary: A case report and a review of the literature
por: Chen, Qiuhe, et al.
Publicado: (2020)

Radiologic Findings of Mesonephric-Like Adenocarcinoma of the Uterine Corpus: A Case Report
Publicado: (2023)

A case of relapsing aseptic meningitis under excellent tumor response to pembrolizumab in microsatellite instability-high recurrent endometrial cancer
por: Noguchi, Daito, et al.
Publicado: (2021)

Bullous Pemphigoid as an Adverse Reaction to Pembrolizumab: Two Case Reports
por: Thomsen, Kenneth, et al.
Publicado: (2018)

PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy
por: Möhn, Nora, et al.
Publicado: (2021)

Mesonephric-like adenocarcinoma of the female genital tract: possible role of KRAS-targeted treatment—detailed molecular analysis of a case series and review of the literature for targetable somatic KRAS-mutations
por: Brambs, Christine E., et al.
Publicado: (2023)

Novel immunohistochemical markers in the differential diagnosis of endocervical and endometrial adenocarcinoma: The added benefit of CAIX and PAX8
por: Hernandez-Caballero, Ana I., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v7hvdaih0eh3dprns6eacbetgd